Document:

Exhibit 10.36

                               Celgene Corporation
                               7 Powder Horn Drive
                            Warren, New Jersey 07059

December 3, 2004

Pharmion Corporation
2525 28th Street
Boulder, Colorado 80301

Pharmion GmbH
Aeschenvorstadt 71
P.O. Box 605
4010 Basel
Switzerland

Gentlemen:

Reference is made to that certain License Agreement, dated as of November 16,
2001, as amended by Amendment No. 1, dated March 3, 2003, as further amended by
Amendment No. 2, dated April 8, 2003, and as further amended by that letter
agreement, dated August 18, 2003, by and among Pharmion GmbH, Pharmion
Corporation ("Pharmion") and Celgene Corporation ("Celgene") (the "License
Agreement"). Except as otherwise indicated, capitalized terms used herein have
the meaning ascribed to them in the License Agreement.

Since the date of the License Agreement, Celgene has continued, and continues,
to make a substantial investment in the development of world-wide intellectual
property rights to the use of Thalidomide in oncology.

Against that background, Pharmion GmbH, Pharmion and Celgene hereby agree as
follows:

1. The Territory is hereby expanded to include Hong Kong, Korea and Taiwan.
Accordingly, the term "Territory" under the definitions set forth in Article I
of the License Agreement is hereby amended in its entirety to read as follows:

         "TERRITORY" shall mean all the countries of the world, except the
         United States, Canada, Mexico, Japan, and all provinces of China other
         than Hong Kong)."

In addition, Section 3.10 of the License Agreement is hereby deleted in its
entirety.

2. In consideration of the parties' mutual interest in extending and expanding
their relationship as a result of Pharmion's substantial investment in building
a distribution infrastructure for Thalidomide sales in key markets in the
Territory, its substantial investment seeking regulatory approval in such
markets, and Pharmion's demonstrated success in

<PAGE>

distributing Thalidomide in certain major markets in the Territory, and in view
of the unanticipated delay in obtaining UK Regulatory Approval, (i) Section
9.3(b) of the License Agreement is hereby amended to eliminate clause (i) in its
entirety, with the subsequent clauses of Section 9.3(b) being appropriately
renumbered and cross-references thereto being appropriately revised, and (ii)
Section 9.4 of the License Agreement is hereby amended to eliminate clause (a)
in its entirety, with the subsequent clauses of Section 9.4 being appropriately
renumbered and cross-references thereto being appropriately revised.

3. In consideration of the amendments set forth in Sections 1 and 2 above,
contemporaneously with the execution and delivery of this letter agreement,
Pharmion shall pay to Celgene U.S. $3,000,000 by wire transfer of immediately
available funds.

4. In the interest of accurately reflecting the agreement of the parties to the
License Agreement with respect to royalties thereunder, Section 3.5 of the
License Agreement is amended in its entirety to read as follows:

         "3.5 Royalties. In consideration of the license and rights granted by
         Celgene to Pharmion pursuant to this Article 3, Pharmion shall pay to
         Celgene a royalty with respect to each country in the Territory, equal
         to eight percent (8%) of Net Sales following the First Commercial Sale
         in such country, payable as provided below."

5. Except as expressly modified by this letter agreement, all terms and
conditions of the License Agreement shall remain in full force and effect.

6. This letter agreement may be executed in two or more counterparts, each of
which shall be deemed to be an original but all of which, together, shall
constitute one and the same agreement.

                                   Sincerely,

                                   Celgene Corporation

                                   By: /s/ Sol J. Barer
                                      -----------------------------------------
                                           Sol J. Barer
                                           President and Chief Operating Officer

Agreed:

Pharmion Corporation
Pharmion GmbH

By: /S/ Patrick J. Mahaffy
   ------------------------------------------
        Patrick J. Mahaffy
        President and Chief Executive OfficerExhibit 10.37

                              Pharmion Corporation
                                2525 28th Street
                             Boulder, Colorado 80301

December 3, 2004

Celgene Corporation
7 Powder Horn Drive
Warren, New Jersey  07059

Attention:  Sol J. Barer

Gentlemen:

Pharmion GmbH ("Pharmion"), Pharmion Corporation ("Guarantor") and Celgene
Corporation ("Celgene") have previously entered into a License Agreement dated
November 16, 2001, as subsequently amended (the "License Agreement") pursuant to
which Celgene has granted to Pharmion a license for Thalidomide products,
including its Thalomid formulation. To further their mutual interests in
Pharmion obtaining regulatory approval for the marketing and sale of Thalomid in
the Territory (as defined in the License Agreement), Pharmion, Guarantor and
Celgene have previously established a working relationship relating to the
clinical development of Thalomid under a letter agreement dated April 2, 2003
("2003 Clinical Trials Agreement"). Subsequently, on the basis of advice from
the European Agency for the Evaluation of Medicinal Products ("EMEA") that it
would require additional clinical data for Thalomid before it could reach an
opinion on whether or not the drug should be approved as a treatment for
multiple myeloma, Pharmion withdrew its Thalomid application in Europe in order
to focus on preparing a new dossier with additional clinical data. Based on
discussions with each other, Pharmion and Celgene have come to recognize that
much of the research and development effort necessary for the regulatory
approval and commercialization of Thalomid, including clinical trials that would
support an EMEA submission, that each desires to be conducted is already being
planned and implemented by Celgene. In order to further coordinate these
development efforts, to insure continued consistency across US and European
centers, and to avoid unnecessary duplication of efforts, Pharmion, Guarantor
and Celgene hereby agree as follows:

1.       The 2003 Clinical Trials Agreement shall remain in full force and
         effect. Capitalized terms therein defined or otherwise defined in the
         License Agreement shall have the same meaning in this letter agreement
         as ascribed to such terms in such documents.

2.       The Thalomid Clinical Development Committee ("TCDC") established under
         the 2003 Clinical Trials Agreement as a forum to review the design,
         development, enrollment and progress of Thalomid clinical trials funded
         in part by Pharmion under the 2003 Clinical Trials Agreement shall also
         function in a similar manner with respect to the clinical trials

<PAGE>

Celgene Corporation
December 3, 2004
Page 2

         contemplated by this agreement, and the provisions of the 2003 Clinical
         Trials Agreement relating to the TCDC are incorporated herein by
         reference in their entirety.

3.       Celgene has shared with Pharmion its summary of, and budget for, its
         003 Phase III multiple myeloma clinical trial plan for Thalomid for the
         years 2005, 2006 and 2007 as currently contemplated by Celgene, and
         also has advised Pharmion of certain other Phase II clinical studies
         that are either underway or contemplated to evaluate the clinical
         potential of Thalomid in treating other solid tumor and blood cancers.
         Through the TCDC, Celgene shall, on a quarterly basis, keep Pharmion
         apprised of the changes in the scope and direction of its currently
         contemplated clinical development plans for Thalomid, the progress of
         such trials, their provisions for compliance with Good Clinical
         Practice requirements, and the data resulting from the such trials.
         Celgene shall consider in good faith the views of Pharmion with respect
         to the overall clinical development plan for Thalomid during the
         forthcoming three calendar years and the suggestions that Pharmion may
         make with regard to the mix of trials, other hematological or solid
         tumor indications for Thalomid that would merit clinical development,
         other new indications or other drug combinations for clinical trials.
         Celgene shall also consider in good faith the views of Pharmion
         concerning possible adjustments of any of the specific trials that may
         be appropriate to address the requirements of the EMEA or other
         regulatory authorities in connection with obtaining regulatory approval
         or label expansion of Thalomid in the Territory. Notwithstanding
         anything to the contrary in this agreement, Celgene shall have sole
         authority with respect to, and control of, such clinical trials.

4.       During the period commencing on January 1, 2005 and ending December 31,
         2007, in addition to any remaining amounts payable by Pharmion to
         Celgene under the 2003 Clinical Trials Agreement, Pharmion and
         Guarantor, jointly and severally, shall reimburse Celgene for an
         aggregate of $8 million (the "Funding") for the expenses and internal
         costs incurred by Celgene for the conduct of Thalomid research and
         development, including clinical trials ("Funded Expenses"). The Funding
         shall be provided in installments of $666,666 each, payable on the last
         day of each calendar quarter in 2005, 2006 and 2007. Celgene shall
         present a statement of Funded Expenses within forty-five (45) days
         after the end of each calendar quarter in the period from the date of
         this letter agreement to December 31, 2007. Such statement shall
         include a summary of expenses incurred for each clinical trial funded,
         at least in part, by Pharmion. Celgene currently anticipates that the
         total Funded Expenses in the three-year period ending December 31, 2007
         to be well in excess of $8 million. However, if at any time during such
         period, Celgene anticipates that the total Funded Expenses for such
         period shall be less than $8 million, Celgene shall confer with
         Pharmion regarding an appropriate adjustment of Pharmion's funding
         obligations under this letter agreement.

5.       To the extent there is any conflict between the terms of this letter
         agreement and the License Agreement, this Agreement shall control.

6.       This letter agreement shall be governed by and construed in accordance
         with the laws of the State of New York.

<PAGE>

Celgene Corporation
December 3, 2004
Page 3

Please indicate your acceptance of, and agreement with, the foregoing by signing
the enclosed copy of this letter and returning it to us.

Very truly yours,

Pharmion Corporation
Pharmion GmbH

By:/s/ Patrick J. Mahaffy
   -----------------------------------------
    Patrick J. Mahaffy
    President and CEO

ACCEPTED AND AGREED:

Celgene Corporation

By:/s/ John W. Jackson
   -----------------------------------------
    John W. Jackson
    Chairman and Chief Executive Officer

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00080-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00080-of-00352.parquet"}]]